World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
98
Citations
48564
World Ranking
774
National Ranking
24

Medicine

D-Index
99
Citations
48676
World Ranking
8444
National Ranking
258

Pascal Chanez publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Pascal Chanez sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 463 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Pascal Chanez D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Pascal Chanez sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 98 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Pascal Chanez is affiliated with Aix-Marseille University in France. The research focus is primarily within the field of Medicine, with a substantial body of work in Pulmonary and Respiratory Medicine, Physiology, Immunology and Allergy, Immunology, and Surgery.

The scientist's research centers on topics including:

  • Asthma and respiratory diseases
  • Respiratory and Cough-Related Research
  • Allergic Rhinitis and Sensitization
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • IL-33, ST2, and ILC Pathways
  • Neonatal Respiratory Health Research
  • Inhalation and Respiratory Drug Delivery

Frequent coauthors collaborating with Pascal Chanez include Arnaud Bourdin, Delphine Gras, Ian M. Adcock, Peter Howarth, and Ratko Djukanović.

Major publication venues where this researcher has contributed extensively include:

  • Revue des Maladies Respiratoires
  • Revue française d'allergologie
  • Revue des Maladies Respiratoires Actualités
  • European Respiratory Review
  • European Respiratory Journal

Notable recent papers authored or coauthored by Pascal Chanez encompass the following works:

  • Eosinophils in Health and Disease: A State-of-the-Art Review, 2021, Mayo Clinic Proceedings
  • Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial, 2020, The Lancet Respiratory Medicine
  • Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study, 2020, The Lancet Respiratory Medicine
  • Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study, 2023, The Lancet Respiratory Medicine
  • Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme, 2020, European Respiratory Journal

Best Publications

  • International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

    Kian Fan Chung;Sally E. Wenzel;Jan L. Brozek;Andrew Bush

  • Eosinophilic inflammation in asthma.

    J Bousquet;P Chanez;J Y Lacoste;G Barnéon

  • Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

    Ian D Pavord;Stephanie Korn;Peter Howarth;Eugene R Bleecker

  • Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

    Hector G. Ortega;Mark C. Liu;Ian D. Pavord;Guy G. Brusselle

  • An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.

    Helen K. Reddel;D. Robin Taylor;Eric D. Bateman;Louis-Philippe Boulet

  • Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

    Eugene R Bleecker;J Mark FitzGerald;Pascal Chanez;Alberto Papi

  • The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

    B Abraham;JM Anto;E Barreiro;Ehd Bel

  • Induction of nitric oxide synthase in asthma

    Q Hamid;Springall;JM Polak;V Riveros-Moreno

  • Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD

    Helgo Magnussen;Bernd Disse;Roberto Rodriguez-Roisin;Anne Kirsten

  • Transforming Growth Factor- β Expression in Mucosal Biopsies in Asthma and Chronic Bronchitis

    A M Vignola;P Chanez;G Chiappara;A Merendino

  • A new perspective on concepts of asthma severity and control

    D. R. Taylor;E. D. Bateman;L.-P. Boulet;H. A. Boushey

  • Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells

    Martijn J. Schuijs;Monique A. Willart;Karl Vergote;Delphine Gras

  • Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

    Dominick E. Shaw;Ana R. Sousa;Stephen J. Fowler;Louise J. Fleming

  • Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.

    Ian D. Pavord;Pascal Chanez;Gerard J. Criner;Huib A.M. Kerstjens

  • Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline

    Fernando Holguin;Juan Carlos Cardet;Kian Fan Chung;Sarah Diver

  • Sputum Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Airflow Obstruction in Asthma and Chronic Bronchitis

    Antonio M. Vignola;Loredana Riccobono;Angela Mirabella;Mirella Profita

  • A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.

    Sally E. Wenzel;Peter J. Barnes;Eugene R. Bleecker;Jean Bousquet

  • Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease.

    Jean-Yves Lacoste;Jean Bousquet;Pascal Chanez;Thierry Van Vyve

  • Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society

    KF Chung;P Godard;E Adelroth;J Ayres

  • Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial

    Henrik Watz;Kay Tetzlaff;Kay Tetzlaff;Emiel F M Wouters;Anne Kirsten

Frequent Co-Authors

Jean Bousquet
Jean Bousquet University of Montpellier
Nicolas Roche
Nicolas Roche Université Paris Cité
Peter J. Sterk
Peter J. Sterk University of Amsterdam
Ratko Djukanovic
Ratko Djukanovic University of Southampton
Kian Fan Chung
Kian Fan Chung Imperial College London
Norbert Krug
Norbert Krug Fraunhofer Society
Thomas Sandström
Thomas Sandström Umeå University
Peter H. Howarth
Peter H. Howarth University of Southampton
Ian M. Adcock
Ian M. Adcock Imperial College London
Sven-Erik Dahlén
Sven-Erik Dahlén Karolinska Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, expanding your education into nursing and healthcare management can open diverse career paths. Many professionals pursue advanced nursing degrees online to specialize further and improve their job prospects.

One popular route is enrolling in online nursing programs for non nurses, which offer accelerated pathways for individuals without a traditional nursing background. These programs lay the foundation for becoming a licensed nurse and advancing in healthcare roles.

After gaining nursing credentials, some aim for specialized fields like acute care. Transitioning through acute care nurse practitioner programs allows nurses to manage complex patient conditions in hospital settings, a highly in-demand specialization.

Many students opt for a faster route by choosing nurse practitioner accelerated program options, cutting down time spent in school while still meeting certification criteria.

Salary expectations vary by location, but those with advanced nursing degrees generally see promising earnings. For example, the dnp salary by state resource offers a clear overview of potential income across the USA, helping candidates plan their career growth strategically.

Best Scientists Citing Pascal Chanez

Trending Scientists